NFKB1 and COVID-19: Since NF-κB drives the expression of cytokines and others inflammatory mediators involved in COVID-19 hyperinflammatory state, targeting NF-κB pathway has been proposed to ameliorate severe inflammation in COVID-19 [108,109].